Montis Biosciences BV has released preclinical data on its lead program, MB-0109, in support of its development to treat neuro-autoimmune indications.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results